WHO ICTRP trial
Personalized extended interval dosing of natalizumab in relapsing remitting…
CTIS2024-513105-31-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-513105-31-00 |
|---|---|
| Public title | Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) |
| Scientific title | Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) |
| Primary sponsor | Amsterdam UMC Stichting |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): Yes |
| Countries | Netherlands |
| Conditions | Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] |
| Interventions | Product Name: Tysabri 300 mg concentrate for solution for infusion, Product Code:PRD10194542, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tyruko 300 mg concentrate for solution for… |
| Registration date | Jul 22, 2024 |
| Target size | 440 |
| Secondary IDs | NCT04225312;2019-002566-13 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: